Lineage Interest Income from 2010 to 2024

LCTX Stock

USD 0.61 0.04 7.02%

Lineage Cell Interest Income yearly trend continues to be fairly stable with very little volatility. Interest Income will likely drop to about 1.5 M in 2024. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2010-12-31

Previous Quarter

1.6 M

Current Value

1.5 M

Quarterly Volatility

24.1 M

Credit Downgrade

Yuan Drop

Covid

Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 9.4 M, as well as many indicators such as Price To Sales Ratio of 19.99, Dividend Yield of 0.0015 or PTB Ratio of 3.12. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.

Check out the analysis of Lineage Cell Correlation against competitors.

Latest Lineage Cell's Interest Income Growth Pattern

Below is the plot of the Interest Income of Lineage Cell Therapeutics over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Lineage Cell's Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Lineage Interest Income Regression Statistics

	Arithmetic Mean	13,885,237
	Geometric Mean	2,980,107
	Coefficient Of Variation	173.43
	Mean Deviation	17,036,940
	Median	3,319,000
	Standard Deviation	24,081,022
	Sample Variance	579.9T
	Range	82.5M
	R-Value	0.02
	Mean Square Error	624.3T
	R-Squared	0.0003
	Significance	0.95
	Slope	93,114
	Total Sum of Squares	8118.5T

Lineage Interest Income History

	2024	1.5 M
	2023	1.6 M
	2022	829 K
	2021	2000.0
	2020	1 M
	2019	17.1 M
	2018	82.5 M

Other Fundumenentals of Lineage Cell Therapeutics

Net Interest Income

Lineage Cell Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Intangible Assets	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Treasury Stock	Property Plant Equipment	Long Term Debt	Net Receivables	Long Term Debt Total	Short Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Good Will
Total Assets		0.86	-0.57	-0.71	0.1	0.55	0.75	0.83	0.45	-0.53	0.13	0.79	-0.81	0.24	0.86	0.61	-0.08	0.48	0.12	0.24	0.59	-0.4	0.4	0.4	-0.05
Total Stockholder Equity	0.86		-0.3	-0.45	0.14	0.14	0.52	0.62	0.04	-0.38	-0.14	0.94	-0.66	-0.1	0.77	0.53	-0.26	0.29	0.06	0.24	0.54	-0.25	0.24	0.1	0.17
Net Debt	-0.57	-0.3		0.47	0.1	-0.52	-0.6	-0.48	-0.55	0.32	-0.1	-0.29	0.55	-0.31	-0.48	-0.25	-0.19	-0.4	-0.2	0.37	-0.09	0.24	-0.17	-0.32	0.23
Retained Earnings	-0.71	-0.45	0.47		0.03	-0.72	-0.62	-0.97	-0.68	0.34	-0.51	-0.36	0.81	-0.62	-0.85	-0.69	0.14	-0.27	0.12	-0.39	-0.5	0.86	-0.09	-0.82	0.48
Accounts Payable	0.1	0.14	0.1	0.03		-0.16	0.03	-0.01	-0.29	-0.32	-0.11	0.16	-0.18	-0.34	0.11	-0.03	0.01	0.1	0.21	-0.04	0.21	0.15	0.1	-0.33	0.28
Total Liab	0.55	0.14	-0.52	-0.72	-0.16		0.76	0.65	0.96	-0.18	0.55	0.02	-0.43	0.84	0.48	0.26	-0.14	0.65	-0.25	0.29	0.4	-0.66	0.5	0.82	-0.31
Total Current Assets	0.75	0.52	-0.6	-0.62	0.03	0.76		0.62	0.64	-0.36	0.42	0.32	-0.61	0.37	0.62	0.46	-0.02	0.8	-0.03	0.35	0.41	-0.49	0.71	0.48	0.15
Common Stock	0.83	0.62	-0.48	-0.97	-0.01	0.65	0.62		0.6	-0.4	0.39	0.56	-0.86	0.52	0.92	0.72	-0.19	0.29	-0.09	0.36	0.55	-0.79	0.13	0.74	-0.44
Current Deferred Revenue	0.45	0.04	-0.55	-0.68	-0.29	0.96	0.64	0.6		0.0	0.45	-0.04	-0.37	0.93	0.42	0.23	-0.14	0.55	-0.26	0.15	0.33	-0.67	0.34	0.86	-0.49
Short Term Debt	-0.53	-0.38	0.32	0.34	-0.32	-0.18	-0.36	-0.4	0.0		-0.15	-0.41	0.55	0.18	-0.42	-0.3	-0.27	-0.14	-0.4	-0.11	0.0	0.0	-0.13	0.11	-0.23
Intangible Assets	0.13	-0.14	-0.1	-0.51	-0.11	0.55	0.42	0.39	0.45	-0.15		-0.39	-0.21	0.43	0.17	0.22	-0.05	0.32	-0.39	0.36	0.27	-0.46	0.32	0.6	-0.16
Net Tangible Assets	0.79	0.94	-0.29	-0.36	0.16	0.02	0.32	0.56	-0.04	-0.41	-0.39		-0.64	-0.15	0.74	0.5	-0.18	0.13	0.22	0.07	0.42	-0.15	0.05	-0.01	0.06
Capital Surpluse	-0.81	-0.66	0.55	0.81	-0.18	-0.43	-0.61	-0.86	-0.37	0.55	-0.21	-0.64		-0.21	-0.95	-0.75	-0.07	-0.22	-0.22	-0.27	-0.5	0.55	-0.1	-0.45	0.23
Deferred Long Term Liab	0.24	-0.1	-0.31	-0.62	-0.34	0.84	0.37	0.52	0.93	0.18	0.43	-0.15	-0.21		0.29	0.1	-0.33	0.31	-0.46	0.2	0.26	-0.71	0.11	0.91	-0.65
Treasury Stock	0.86	0.77	-0.48	-0.85	0.11	0.48	0.62	0.92	0.42	-0.42	0.17	0.74	-0.95	0.29		0.77	-0.13	0.27	0.07	0.34	0.62	-0.67	0.13	0.54	-0.26
Property Plant Equipment	0.61	0.53	-0.25	-0.69	-0.03	0.26	0.46	0.72	0.23	-0.3	0.22	0.5	-0.75	0.1	0.77		0.28	0.18	0.35	0.32	0.44	-0.51	0.06	0.39	-0.24
Long Term Debt	-0.08	-0.26	-0.19	0.14	0.01	-0.14	-0.02	-0.19	-0.14	-0.27	-0.05	-0.18	-0.07	-0.33	-0.13	0.28		-0.16	0.88	-0.2	-0.16	0.4	-0.08	-0.33	0.16
Net Receivables	0.48	0.29	-0.4	-0.27	0.1	0.65	0.8	0.29	0.55	-0.14	0.32	0.13	-0.22	0.31	0.27	0.18	-0.16		-0.2	0.05	0.28	-0.25	0.88	0.3	0.15
Long Term Debt Total	0.12	0.06	-0.2	0.12	0.21	-0.25	-0.03	-0.09	-0.26	-0.4	-0.39	0.22	-0.22	-0.46	0.07	0.35	0.88	-0.2		-0.23	-0.05	0.39	-0.17	-0.45	0.23
Short Term Investments	0.24	0.24	0.37	-0.39	-0.04	0.29	0.35	0.36	0.15	-0.11	0.36	0.07	-0.27	0.2	0.34	0.32	-0.2	0.05	-0.23		0.33	-0.46	0.27	0.37	0.19
Short Long Term Debt	0.59	0.54	-0.09	-0.5	0.21	0.4	0.41	0.55	0.33	0.0	0.27	0.42	-0.5	0.26	0.62	0.44	-0.16	0.28	-0.05	0.33		-0.4	0.28	0.45	-0.06
Net Invested Capital	-0.4	-0.25	0.24	0.86	0.15	-0.66	-0.49	-0.79	-0.67	0.0	-0.46	-0.15	0.55	-0.71	-0.67	-0.51	0.4	-0.25	0.39	-0.46	-0.4		-0.03	-0.88	0.51
Net Working Capital	0.4	0.24	-0.17	-0.09	0.1	0.5	0.71	0.13	0.34	-0.13	0.32	0.05	-0.1	0.11	0.13	0.06	-0.08	0.88	-0.17	0.27	0.28	-0.03		0.13	0.37
Capital Stock	0.4	0.1	-0.32	-0.82	-0.33	0.82	0.48	0.74	0.86	0.11	0.6	-0.01	-0.45	0.91	0.54	0.39	-0.33	0.3	-0.45	0.37	0.45	-0.88	0.13		-0.65
Good Will	-0.05	0.17	0.23	0.48	0.28	-0.31	0.15	-0.44	-0.49	-0.23	-0.16	0.06	0.23	-0.65	-0.26	-0.24	0.16	0.15	0.23	0.19	-0.06	0.51	0.37	-0.65

Click cells to compare fundamentals

About Lineage Cell Financial Statements

Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Interest Income	1.6 M	1.5 M
Net Interest Income	1.6 M	1.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Lineage Stock Analysis

When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lineage Interest Income from 2010 to 2024

Latest Lineage Cell's Interest Income Growth Pattern

Lineage Interest Income Regression Statistics

Lineage Interest Income History

Other Fundumenentals of Lineage Cell Therapeutics

Lineage Cell Interest Income component correlations

About Lineage Cell Financial Statements

Also Currently Popular

Additional Tools for Lineage Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY